Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026 ...

PureTech Health (PRTC) noted that its founded entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia ...

In a challenging year for biotechnology firms, PureTech Health PLC (PRTC) stock has touched a 52-week low, dipping to $16.81.

In a challenging year for biotechnology firms, PureTech Health PLC (PRTC) stock has touched a 52-week low, dipping to $16.81. With a market capitalization of $4.15 billion, the company maintains a ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...

Web Punditstm, a trusted provider of Remote Desktop Protocol (RDP) services, announces the launch of its cost-effective and high-performance RDP solutions designed ...

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

Biosciences' lead drug candidate, VE303, has been reported to demonstrate efficacy in preventing recurrent Clostridioides ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment ...

Check the time stamp on this data. Updated AI-Generated Signals for Puretech Health Plc (PRTC) available here: PRTC. Type a ...

PureTech meanwhile is also exploring the use of LYT-100 in other indications, including as a treatment for respiratory complications of long COVID and breast cancer-related, upper limb secondary ...